drugset
drugset / Trial / NCT07465731

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

NCT07465731 ↗

Phase 1 Completed 62 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this trial is to assess relative bioavailability of centanafadine (CTN) SR tablet to CTN QD XR capsule in healthy adult participants.

Timeline

Start
2022-10-27
Primary completion
2023-03-26
Completion
2023-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 164.4 mg Oral
Subject Centanafadine Small molecule 200 mg Oral
Subject Centanafadine Small molecule 328.8 mg Oral
Subject Centanafadine Small molecule 400 mg Oral

Indications

No indication recorded.